KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Retained Earnings

Last Annual Value

-160.00M

3-Year CAGR

-70%

5-Year CAGR

-5%

10-Year CAGR

-2%

KT

Kalaris Therapeutics Inc Competitors Analysis of Retained Earnings

KLRS · NASDAQ
CompanyRetained Earnings
CAGR 3Y
CAGR 5Y
CAGR 10Y
-160.00M
N/AN/AN/A 
-321.71M
N/AN/AN/A
-330.55M
N/AN/AN/A
-430.53M
N/AN/AN/A
-130.90M
N/AN/AN/A
-310.87M
N/AN/AN/A
-1.07B
N/AN/AN/A
-722.82M
N/AN/AN/A
-556.26M
N/AN/AN/A
-289.23M
N/AN/AN/A
-123.44M
N/AN/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7